TrialThe oncologist2023

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.

Serena Di Cosimo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.